Cowen analyst Joshua Jennings lowered the firm’s price target on Baxter to $45 from $70 and keeps an Outperform rating on the shares. The analyst said the first half of 2023 should be worse than the second so we see a potential recovery path over the course of the year with the caveat that the spinoff may bring new unknowns in 2024.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on BAX: